Conference Reports for NATAP
Back
 
(APASL) 24th Conference of the Asian Pacific Association
for the Study of the Liver
12-15 March, 2014, Brisbane, Australia
Clinical Characteristics of Patients Who Developed HCC While Receiving Tenofovir Disoproxil Fumarate (TDF) Up to 336 Weeks of Therapy
- (01/08/15)
 
A Single Direct-acting Anti-viral Agent, ACH-3102, with Ribavirin is Able to Achieve a Robust Anti-viral Response in Subjects with Genotype 1b Chronic Hepatitis C Infection
- (04/17/14)
 
ACH-3102 and Ribavirin in Genotype-1b Hepatitis C Patients: Confirmation of the High Barrier to Viral Breakthrough in Genotype-1b HCV
- (04/17/14)
 
SVR4 Results for the Combination of ACH-3102 and Sovaprevir, With Ribavirin, in Patients With Genotype 1 Chronic Hepatitis C Infection
- (04/17/14)
 
Simeprevir with Peginterferon/Ribavirin for Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Treatment-Experienced Patients: Interim Results of a Phase III Rollover Trial
- (03/25/14)
 
Simeprevir (TMC435) with peginterferon-α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy in patients with genotype 1b HCV in the PROMISE Phase III trial
- (03/25/14)
 
Twenty-Eight Day Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B Patients
- (03/19/14)
 
High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ± RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study
- (03/19/14)
 
Sofosbuvir Plus Ribavirin For HCV Genotype 1-3 Infection in HIV Co-infected Patients (PHOTON-1)
- (03/19/14)
 
Once-Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With or Without Ribavirin Resulted in 97% Sustained Virologic Response in Patients With HCV Genotype 1, Including Patients With Cirrhosis: The LONESTAR Trial
- (03/19/14)
 
A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study
- (03/19/14)
 
Simeprevir (TMC435) with peginterferon-α/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in patients with genotype 1b HCV in the QUEST-1 and -2 Phase III trials
- (03/19/14)
 
High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ± RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study
- (03/17/14)
 
Efficacy and Safety of an Interferon-Free Regimen of MK-5172 + Ribavirin for 12 Weeks or 24 Weeks in Treatment-Naive, Noncirrhotic Subjects With HCV GT1 Infection: The C-SPIRIT Study
- (03/17/14)
 
Faldaprevir Plus Pegylated Interferon α-2a/Ribavirin in HIV/HCV Co infection: STARTVerso4
- (03/17/14)
 
Interferon- and Ribavirin-Free Regimen of ABT-450/r and ABT-267 in Treatment-Experienced Japanese Patients Infected With HCV Genotype 1b or Genotype 2
- (03/17/14)
 
Pharmacokinetics of ABT-450/r and ABT-267 in Treatment-Experienced HCV Subgenotype 1b- and Genotype 2-Infected Japanese Subjects
- (03/17/14)
 
Concordance of SVR12 With SVR4 and SVR24 in Patients With Chronic HCV Genotype 1b Treated With the Interferon- and Ribavirin-free ABT-450/r and ABT-267 Regimen
- (03/17/14)
 
Once Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin in Patients With Inherited Bleeding Disorders and HCV Infection
- (03/17/14)
 
High Sustained Response Rates With Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3 Infection: The VALENCE Trial
- (03/17/14)
 
Sofosbuvir in Combination With Pegylated Interferon-alfa and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment-Experienced Patients With and Without Compensated Cirrhosis: Results From the LONESTAR-2 Study
- (03/17/14)
 
Once Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With or Without Ribavirin: Data From the ELECTRON Trials
- (03/17/14)
 
Cross-Study Analysis of the Efficacy of the All-Oral Combination of Daclatasvir (DCV) and Asunaprevir (ASV) in Patients with HCV Genotype 1b Infection
- (03/17/14)
 
On-Treatment Predictors of Response to Daclatasvir (DCV) in Combination With Asunaprevir (ASV) in Japanese Patients With Genotype 1b Infection
- (03/17/14)
 
Investigating treatment strategies to optimise clinical outcomes associated with emerging therapies for HCV
- (03/17/14)
 
Efficacy and Safety of Daclatasvir (DCV) in Combination With Asunaprevir (ASV) in Cirrhotic and Non-Cirrhotic Patients With Hepatitis C Virus (HCV) Genotype 1b Infection
- (03/17/14)
 
Effect of Demographic and Baseline Disease Characteristics on the Efficacy and Safety of Daclatasvir in Combination With Asunaprevir in Japanese Patients With HCV Genotype 1b Infection
- (03/17/14)